8-K filing — Aditxt, Inc. (ADTX)
Filed: 2026-08-19 AccNo: 0001213900-26-091703 Size: 194 KB Item 8.01: Other Events
Stocks · News reference
Copley Acquisition To Merge With Ignite Proteomics At Pro Forma EV Of $150M
Copley Acquisition Corp (NYSE:COPL) ("Copley"), a special purpose acquisition company and Ignite Proteomics, LLC ("Ignite" or "Ignite Proteomics"), a leader in pathway-level protein analytics to guide precision oncology,
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Nasdaq Surges 300 Points; US Initial Jobless Claims Edge Lower
US stocks up, Nasdaq gains over 300 points. Dow up 0.51%, Nasdaq up 1.17%, S&P 500 up 0.94%. Tech sector jumps 2.3%, energy stocks down 2%. US jobless claims fall by 4,000, Philadelphia Fed index rises to 10.3. Mixed performance in European and Asian markets.
Crude Oil Edges Higher; US Retail Sales Top Estimates
U.S. stocks up, Dow Jones gains 0.39%. NASDAQ rose 0.09%, S&P 500 up 0.11%. Industrials shares jump 0.9%, while communication services fall 1.7%.
US Stocks Edge Higher; CarMax Posts Upbeat Earnings
US stocks gain in morning trading, Dow up 0.1%. Tech sector leads gains, while communication services fall. CarMax beats earnings expectations.
Copley Acquisition Corp (NYSE: COPL) and Ignite Proteomics Announce Business Combination Agreement to Advance Precision Oncology
Copley Acquisition Corp (NYSE: COPL) and Ignite Proteomics have announced a definitive business combination agreement. Upon closing, the companies will form Ignite Proteomics Holdings, Inc. (PubCo), to be listed on the NYSE. The transaction values Ignite at a $150 million pro forma enterprise value and is expected to close in the second half of 2026. Ignite Proteomics specializes in pathway-level protein analytics for precision oncology.